Introduction
Immunological memory, or the ability to generate increasingly efficient antigen-specific protective immune responses with subsequent antigenic exposures, is a fundamental hallmark of adaptive immunity in higher vertebrates. The effect of an initial exposure to an environmental antigen is imprinted on a host organism's immune cell repertoire in such a way so as to increase the magnitude and rapidity of antigen clearance following reexposure to that antigen. In particular, antigen-experienced T cells take on characteristics indicative of prior activation and give rise to a population of cells collective referred to as memory T cells (T M s). These cells mediate enhanced protection against invading pathogens and are thought to convey an evolutionary survival advantage. However, in the context of transplantation, the presence of cells with prejudiced reactivity against donor antigens increases the likelihood of immune-mediated rejection such that adaptive immunity becomes counter adaptive. Although the precise pathways and cellular interactions that shape T M s function rejection remain to be fully elucidated, emerging evidence suggests that these cells play a critical role in rejection. In this review, we describe fundamental characteristics of T M s, discuss their role in allograft rejection, and relate their unique traits to existing and emerging immune therapeutic agents.
Characteristics of memory T cells
T cells emerge from the thymus with a naive or nonactivated phenotype characterized by relatively high T-cell receptor (TCR) density and limited adhesion molecule expression. This phenotype persists until the cell becomes primed. Priming requires repetitive binding of a cell's TCRs to major histocompatibility complex (MHC) molecules presenting the T cell's cognate peptide antigen in the context of sufficient costimulatory signals, accessory molecules, and adhesion molecules to induce cell division. Following several rounds of division, naive T cells differentiate into an activated, effector T-cell population that then mediates antigen elimination. Most of these cells undergo apoptosis in the conduct of their effector function, leading to population contraction with antigen elimination. However, some cells persist as a pool of long-lasting antigen-specific T M s. Two models have been suggested to describe the generation of T M s from naive precursors: a linear progression model postulating that memory populations arise from a pool of previously primed effectors and a parallel progression model stipulating that memory populations develop as a separate lineage alongside the population of short-lived effectors [1] [2] [3] . In addition, recent evidence suggests that the development of T M s may be influenced by antigen-specific T-cell precursor frequency, the extent of antigenic stimulation, the cytokine milieu present at the time of priming, or all [4] [5] [6] . Antigen-specific T-cell memory is maintained within the host by a basal homeostatic turnover that is thought to be supported independent of antigen by cytokines including interleukin (IL)-15 [7] [8] [9] [10] [11] .
As compared with naive T cells, T M s possess distinct phenotypic, functional, and homing properties (Fig. 1 ) [9, 10] . They produce cytokines faster than naive T cells, potentially from decreased activation thresholds [12 ] , and possess direct cytolytic function in vivo following reencounter with antigen [13, 14] . They also express higher levels of CD2, CD11a, and CD44 as compared with their naive counterparts and in humans express the RO isoform of CD45 as opposed to the RA isoform [10, [15] [16] [17] [18] . Numerous groups [19] [20] [21] [22] [23] [24] [25] [26] 27 ] have demonstrated that altered expression of selectins, integrins, and chemokine receptors on T M s is likely responsible for their unique homing properties including residence in peripheral tissues, allowing them more immediate access to peripheral antigen including alloantigen following transplantation. Although T M s are heterogeneous, two well described subsets exist within most antigen-specific memory populations. Central memory T cells (T CM ; CCR7 þ CD62L hi ) migrate primarily to secondary lymphoid tissues (e.g. lymph node and spleen) and are responsible for generating a burst of new effectors following recall. Effector memory T cells (T EM ; CCR7 À CD62L lo ) migrate to nonlymphoid tissues and provide immediate effector function at peripheral sites [19, 26, 27 ]. Whether these two populations derive from one another or have distinct origins is unclear, and there is evidence to support both paradigms [4, 28, 29] .
In unsensitized transplant recipients, two unique mechanisms for the generation of donor-reactive T M s have been described. First, heterologous immunity is the phenomenon, whereby previous exposures to environmental pathogens influence the course of future immune responses to seemingly unrelated antigens [30] [31] [32] . Once thought to be exquisitely specific for a single peptide-MHC complex, TCRs are now appreciated to possess inherent degeneracy with regard to their recognition of antigen, such that a T cell that recognises one antigen can also respond to other antigens, although with altered affinity. Heterologous alloimmunity thus results when a T M population primed by self-MHC, presenting an environmental antigen, generates cross-reactive T M s responsive to allo-MHC or self-MHC presenting an allopeptide. Recently, dual receptor T cells have been described as being overrepresented in alloreactive T-cell populations, raising the possibility that if a dual receptor T cell is activated via one pathogen-specific TCR, then it could later respond as a T M if its second, alloreactive TCRs were to encounter donor antigen [33 ] .
Donor-reactive T M s can also be generated via homeostatic proliferation, a process whereby transient lymphopenia caused by viral infection, or in the case of transplantation, therapeutic T-cell depletion, induces the proliferation and differentiation of naive T cells into cells with true phenotypic and functional characteristics of T M s as well as cells that appear to be T M s but fail to have robust effector functions [34] [35] [36] . Therefore, a proportion of the naive alloreactive T-cell pool is likely stochastically converted into alloreactive T M s throughout life, giving most patients some degree of alloresponsive memory, although they have not had exposure to alloantigen.
Role of memory T cells in allograft rejection
A growing body of evidence exists to suggest that T M s may play a critical role in inhibiting allograft acceptance. Naive T cells express the CD45RA isoform, have relatively high expression of the TCR, low CD2 expression, and require substantial stimulation to produce cytokines and other effector molecules. With memory differentiation, T EM and T CM assume the CD45RO isoform, increase their expression of CD2, and reduce their expression of the TCR. Their capacity to produce cytokines is augmented. T CM express CD62L and CCR7 facilitating their homing to secondary lymphoid tissues, whereas T EM lack these molecules and reside in the periphery. CCR7, chemokine (C-C motif) receptor 7; T CM , central memory T cell; T EM , effector memory T cell; TCR, T-cell receptor.
ability to migrate into allograft tissues and secrete inflammatory cytokines well before the 4-6 days required for donor-specific priming in the spleen [27 ] . Furthermore, tolerance achieved in cardiac allografts using anti-CD154 is rejected when alloreactive T M s are generated in recipients via sensitization with donor-type skin grafts [37, 38] . In addition, regimens to induce tolerance have been highly successful in rodents, but less so in nonhuman primates (NHPs). One possible explanation for this is that longer lived, socially housed animals such as NHPs have, in general, greater exposure to environmental pathogens as compared with rodents housed in specific pathogen-free facilities, and, therefore, possess an increased opportunity to generate a diverse repertoire of T M s [39, 40] . Evidence that supports this hypothesis includes experiments in rodents in which tolerance was achievable in naive animals treated with cytotoxic T-lymphocyte antigen 4 (CTLA4)-immunoglobulin, anti-CD40L mAb, busulfan, and donor bone marrow, but not in animals infected with lymphocytic choriomeningitis virus (LCMV), vaccinia virus, and vesicular stomatitis virus. Even after antiviral immune responses were allowed to resolve to memory, the mice resisted tolerance induction. Stimulation of splenocytes isolated with these recipients with donor tissue resulted in increased frequency of cytokine producing cells, thus implicating the virus-elicited allo-crossreactive T M s in the prevention of tolerance induction in this model [41] .
Similar inhibition of tolerance has been demonstrated in rodents by donor-reactive T M s generated through homeostatic proliferation. In an experimental model in which recipients were devoid of endogenous T cells, adoptive transfer of naive syngeneic splenocytes resulted in the rapid homeostatic expansion of the transferred cells and acquisition of a memory phenotype. Importantly, when these animals were challenged with allogeneic skin grafts, the transplants were rejected despite treatment with costimulation blockade [34] . These data provide direct experimental evidence that donor-reactive memory T cells can be generated by homeostatic mechanisms.
Effects of immunosuppressants on memory T cells
Given that, T EM have unique properties, it is not surprising that they also have characteristic sensitivities to various immune therapeutics that distinguish them from naive cells.
T cell-depleting agents
Many agents are used in clinical transplantation to intentional evoke global T-cell depletion. These include polyclonal antibody preparations such as antithymocyte globulins and mAbs specific for CD3 (muromonab) or CD52 (alemtuzumab). These agents mediate depletion through a variety of mechanisms [42, 43] , and although the T-cell depletion that occurs following treatment with these drugs is profound, emerging evidence suggests that T M s may have some degree of resistance to depletional therapies. For example, treatment of human transplant recipients with alemtuzumab resulted in more than 90% of T-cell depletion; however, the cells that remain have been shown to contain a predominance of CD4
lo T EM s. The origin of the T M predominance probably stems from a combination of T M resistance to antibody-mediated depletion and resultant homeostatic activation of nondepleted cells. The proliferating population is likely derived from naive cells as these cells, being less terminally differentiated, should be expected to have greater proliferative capacity. On the basis of these and other studies [44] [45] [46] , it is accepted that T-cell depletional therapy will increase the overall frequency of T M s, both due to the relative resistance of T M s as well as the likely conversion of naive to T M s via homeostatic activation. A recent study [46] has also suggested that alemtuzumab may decrease the requirement for immunosuppression by downregulating the CD4 þ T EM population associated with rejection. In a human cohort receiving alemtuzumab for kidney transplantation, CD8
þ T cells recovered to their baseline population in 6 months, whereas the recovery of CD4 þ T cells was delayed until approximately 15 months. Furthermore, the CD8 þ T cells that repopulated the peripheral T-cell compartment by homeostatic proliferation were of immunosenescent CD28
À /CD8 þ phenotype, which the investigators postulated may compete for space with or even may suppress the proliferation of CD4 þ T EM cells [47 ] . Alternatively, the absence of CD28 may render these cells resistant to costimulation blockade-based therapies while remaining sensitive to calcineurin inhibitors (CNIs). Importantly, postdepletional T cells are T EM skewed and clearly capable of mediating rejection despite exceptionally low numbers of cells without some adjuvant immunosuppressive therapy [48, 49] . Thus, although their long-term characteristics may be altered in ways that influence their sensitivity to immunosuppressants, they remain immunocompetent.
Effects of T-cell costimulatory pathway blockade
Costimulation is required for optimal activation of naive antigen-specific T cells. The role of costimulation in the activation of T M s is dependent on both the type of T M and the costimulatory molecule. The CD28 pathway is one of the most important and well studied of the T-cell costimulatory pathways. CD28 binds to its ligands CD80 or CD86 and propagates a positive costimulatory signal into the T cell. Agents have been developed to target this pathway. These include CTLA4-immunoglobulin, a fusion protein containing the extracellular domain of the CTLA-4 molecule, which associates tightly with CD80 and CD86 and, therefore, prevents CD28 ligation, and LEA29Y, a second-generation derivative of CTLA-4-immunoglobulin with increased affinity for CD86 [50] . However, evidence from several studies exists to suggest that T M s are relatively independent of CD28-mediated costimulation for recall responses, thus refractory to the effects of CD28 pathway blockers. In rodents deficient in CD28, this costimulatory pathway is not necessary for the generation or recall of T M s [7, 51, 52] . Furthermore, tolerance induction protocols based on CTLA-4-immunoglobulin have been found to be ineffective in recipients that possess cross-reactive virus-elicited donor-reactive T M s. Rejection in these recipients was characterized by a lack of attenuation of donor-reactive CD8 þ T-cell responses; however, CD4 þ donor-reactive T M responses were significantly reduced following this costimulation blockade-based regimen [41] . In another study [53] , CTLA4-immunoglobulin was found to inhibit proliferation and expansion of memory CD4 T cells in response to peptide antigen challenge, with no effect on early activation. Taken together, these data suggest that the type and character of the donor-reactive T M population may influence its relative requirement for CD28-mediated costimulation upon recall. In humans and NHPs, which contain a large population of T M s in their peripheral T-cell repertoires, CTLA4-immunoglobulin and LEA29Y have been shown to prolong graft survival, but not to the extent evident in mouse models. Interestingly, the T EM population in NHPs is largely void of CD28 and thus unlikely to be sensitive to agents targeting this pathway [54 ] . In humans, many CD8 þ T EM s are CD28 À , whereas CD4 þ T EM s tend to retain CD28 expression. Although systematic measurement of the effect of CD28 pathway blockade in humans and NHPs has not been performed, it is clear that adjuvant immune modulatory agents are required to complement the effect of costimulation blockade [55, 56] .
The CD154-CD40 costimulation pathway is also intimately involved in the activation of T cells. In rodent models, inhibition of CD154 with anti-CD154 blocking antibodies has shown to be effective in the prevention of rejection in presensitized hosts, but ineffective in sensitized hosts, indicating that CD154 may not be necessary for the activation of memory T cells [39, 40, 57] . Initial CD154 blocking agents did not undergo development, and their brief investigation in human transplantation suggested a lack of efficacy [58] . As such, other modes of blocking CD154 such as blocking CD40 have been attempted, and have shown promise in long-term kidney allograft tolerance in NHPs [59] . Recent success using a fully human CD40-specific mAb suggests that this approach has promise, but remains dependent on adjuvant therapy [60 ,61] . However, the direct effects of blocking CD40 and CD154 on donor-reactive T M s have varied depending on the model used. Using mice infected with LCMV, investigators have demonstrated that the CD4 T M response was downregulated as compared with the CD8 response when given anti-CD154 agents [62] . In contrast, using a murine cardiac allograft model, the T M response was unchanged with anti-CD154 therapy [63] . These findings suggest that the type and rate of antigen exposure, combined with the heterogeneity of the host T M population, may demonstrate variable sensitivity to blockade of the CD154-CD40 pathway.
Another costimulatory molecule that has been shown to be important in the activation of memory T cells is the OX40 pathway, a member of the tumor necrosis factor receptor superfamily. This pathway has been implicated in synergistically driving the proliferation of T M s along with CD28-mediated costimulation [64] . In murine models, T M -mediated graft rejection was prevented when OX40 blockade was given combined with CD28-CD40 blockade, whereas grafts were rejected when OX40 blockade was given alone [65] .
Although there is a growing body of evidence to suggest that T M s are relatively resistant to costimulation blockade, other agents have been designed to specifically target and deplete the memory compartment based on unique enhanced expression of certain integrins, specifically CD11a and CD2 [66] [67] [68] . Lymphocyte functionassociated antigen 3 (LFA-3)-immunoglobulin G1 fusion protein (alefacept) binds to CD2 and has been shown to both prevent the activation of T M s and induce apoptosis, thereby decreasing the T M population [68, 69] . Alefacept is currently approved for clinical treatment of psoriasis, and its therapeutic effect is linked to its ability to deplete T M [69, 70] . Recently, alefacept has been shown to extend kidney allograft survival in NHPs when added to a CTLA4-immunoglobulin-based regimen [54 ] . In this study, CD4 þ and CD8 þ T EM s were shown to be specifically depleted by alefacept, and this appeared to be related to the increased expression of CD2, the target of alefacept, on T EM populations. Further in-vitro studies of this model examined the effect of alefacept on alloreactive cytokine-producing cells and demonstrated that responding alloreactive CD4 þ and CD8 þ T cells also exhibited increased CD2 expression, thus providing an increased available target for the effects of alefacept. This study was the first to specifically target T M s with the prospective intent on neutralizing cells resistant to costimulation blockade [54 ] .
Effects of blocking signaling through the T-cell receptor and cytokine receptors
The most commonly used immunosuppressants, the CNIs (cyclosporine A and tacrolimus), target TCRmediated signaling. These agents prevent the nuclear translocation of nuclear factor of activated T cells that is required for gene transcription of IL-2, which is important for optimal expansion and survival of T cells. The reduced requirements of T M s for costimulation focus a greater reliance on the TCR, and as such, CNIs have been shown to be unique among the clinically available immunosuppressants in preventing T M proliferation and cytokine production [45] . This factor has been suggested to be a predominant reason why CNIs have been such important contributors to the prevention of rejection in humans. However, although TCR signal inhibition prevents T M activation, it may also inhibit T M apoptosis and response contraction [71] . Thus, the CNI approach appears to have exquisite ability to prevent rejection, but may also prevent regulation and T M contraction through apoptosis.
Inhibiting non-TCR signals in the T cells may have paradoxical influence of T M function and in fact enhance some aspects of immunity. A recent example involves sirolimus, a clinically used immunosuppressant, known to attenuate downstream signaling events through mTOR, thereby preventing G1!S transition required for T-cell proliferation and population expansion. Sirolimus has been used as a replacement for CNIs with one rationale being to specifically allow TCR signaling to foster activation-induced cell death. Although there are few studies assessing the direct effects of these agents on the memory cell population despite their common use, it has recently been demonstrated in an infection model that sirolimus alone acts to actually increase the frequency of antigenspecific T cells that differentiate into the memory lineage [72 ] . In this study, mice given low-dose sirolimus following acute LCMV infection demonstrated enhanced quality and quantity of virus-specific T M s as compared with untreated controls. Similarly, NHPs given sirolimus after modified vaccinia Ankara vaccination exhibited an increased frequency of memory T cells.
Like sirolimus, the CD25-specific mAbs daclizumab and basiliximab also interfere with the IL-2 pathway by binding the high-affinity a chain of the IL-2 receptor (CD25) [73] . Although CD25 is upregulated in both naive and T M s upon encounter with antigen, T M s upregulate CD25 faster and have been shown to subvert the blocking effects of anti-CD25 mAbs through higher expression of the low-affinity IL-2 receptor subunits (CD122 and CD132) that may support T M proliferation and activation by ligating IL-15 in addition to IL-2 [74] . Thus, the extent to which T M s are relevant to an individual's clinical outcome may significantly influence the relative success of CNI-sparing regimens, in general, and sirolimus or anti-CD25-based regimens specifically.
Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that regulate gene expression after signaling by cytokines. JAK3, expressed primarily in hematopoietic cells, is downstream of the common g chain (CD132). Therefore, blocking JAK3 has the potential to interrupt the signals of a broader array of cytokines used by T M s such as IL-2, IL-7, and IL-15. Indeed, JAK3 kinase inhibitors have been shown to prevent allograft rejection in both murine and NHP models [75, 76] . Further studies have proposed that prolonged graft survival observed following administration of JAK3 inhibitors could be due to blockade of signaling through the IL-7 and IL-15 receptors and thus target T M methods for bypassing a requirement for CD25. For instance, recent investigations have suggested that IL-7 is critical both to the generation of T M s following homeostatic proliferation, to aid the survival of T M s, and that IL-15 is required for the generation and maintenance of antiviral CD8 T M s [77] . Currently, one such inhibitor of the JAK3 pathway (CP-690550) is in phase II clinical trials of renal transplantation [78 ] .
It has yet to be specifically investigated for its role in thwarting allospecific memory, but may offer a means of targeting T M s without TCR inhibition.
Effects of blocking T-cell trafficking
Given the role of T EM s in initiating effector function in the periphery and the role of T CM s in rapidly deriving new effectors, interruption of trafficking could have selectively potent effects of T M function. As discussed above, inhibition of LFA-3 interactions with CD2 appear to effectively target T M s and facilitate costimulationbased therapies. Several other agents currently under study for use in transplantation target similar processes. One such treatment is FTY720, which binds sphingosine-1-phosphate receptor as an agonist and disables the SIP receptor from performing its function of allowing lymphocyte migration from the thymus and peripheral lymphoid tissues, effectively sequestering T cells in the lymph nodes, and inhibiting them from trafficking to peripheral graft sites [26, 79, 80] . Blockade of CD11a also may hold promise as an agent that targets the trafficking of T M s. For example, recent work has demonstrated in murine models of transplantation that anti-LFA-1 mAbs result in attenuation of donor-reactive memory recall responses and decreased T-cell trafficking to the allograft following graft placement [81, 82] . The initial phase 2 testing of the anti-LFA-1 agent efalizumab in renal transplantation suggests that this agent indeed has potent inhibitory effects on protective memory in that its combination with a standard immunosuppressive regimen evoked a higher rate of EBV-associated malignancy [83] . Thus, memory inhibition is likely to require cautious paring with other agents to avoid pathologic inhibition of protective immunity.
Conclusion
Memory T cells can pose a critical barrier to successful organ transplantation. The population of T M s of a given individual may vary based on the prior immune history of that patient, including the type and frequency of environmental exposures to pathogens. The alloreactivity of the T M population may also vary based on heterologous cross-reactivity or direct prior alloantigen exposure. Regardless, the importance of a thorough understanding of the mechanisms of donor-specific T M generation and the effects of immunosuppressive agents on these heterogeneous populations is becoming increasingly apparent. Closer attention to memory responses will likely enhance the potential to tailor immunomodulatory strategies for a given transplant recipient. This study conducted in humans demonstrates a mechanism to account for the depletional effects of anti-CD52 agents, and why the memory T-cell response is blunted against allograft. Further, this study shows that depletional agents can decrease the requirement for chronic immunosuppression.
